Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BZ-4 TCR-engineered CD8+ T cells
- Development stage
- Unknown
- Lead developer
- National Heart
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BZ-4 TCR-engineered CD8+ T cells are an autologous T-cell receptor (TCR) therapy developed by the NIH National Heart, Lung, and Blood Institute (NHLBI). The therapy involves CD8+ T cells genetically modified to express the BZ-4 TCR, which was originally isolated from a patient who experienced immune-mediated regression of renal cell carcinoma (RCC) after an allogeneic stem cell transplant. This TCR specifically recognizes the CT-RCC-1 peptide, a 10-mer derived from human endogenous retrovirus type E (HERV-E), presented in the context of HLA-A11. The drug is currently being evaluated in a Phase I clinical trial for patients with metastatic renal cell carcinoma.
- Other names
- BZ-4 TCR-transduced CD8+ T cellsBZ-4 TCR-modified CD8+ T cells
02
Targets
HLA-A*11
Beyond the preview
Go deeper on BZ-4 TCR-engineered CD8+ T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BZ-4 TCR-engineered CD8+ T cells.